BMX 001

Drug Profile

BMX 001

Alternative Names: BMX-001

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Duke University
  • Developer BioMimetix
  • Class Antineoplastics; Metalloporphyrins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma

Most Recent Events

  • 08 Dec 2016 BioMimetix plans a phase I trial for Head and neck cancer (Newly diagnosed; Locally advanced) in USA (NCT02990468)
  • 01 May 2016 Phase-I/II clinical trials in Glioma (Late-stage disease, Newly diagnosed, Adjunctive treatment) in USA (SC) (NCT02655601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top